Gastrointestinal Tract News and Research

RSS

World's smallest gastrointestinal videoscope with four-way angulation and NBI

Olympus today introduced the world's smallest gastrointestinal videoscope to offer four-way angulation and Narrow Band Imaging™ (NBI) to detect upper gastrointestinal abnormalities. The super-slim scope is 5.5 mm in diameter at the distal end, as well as the insertion tube, and offers exceptional insertion capability to enhance patient comfort. The scope also features NBI, Olympus' proprietary imaging technology that filters white light to consist of specific wavelength bands enabling enhanced observation of microvessels and subtle changes on the mucosa.

From Evident Corporation - Life Sciences 11 Nov 2009

ImmunoLin provides immediate benefit to the function of immune system and gut

A new study provides evidence that ImmunoLin®, an all natural and GRAS approved source of immunoglobulin, will provide immediate benefit to the function of the immune system and the gut. Immunoglobulins, or antibodies, are specialized proteins found in blood that the immune system naturally produces for immunity.

6 Nov 2009

Nano-size capsule that boosts the body's uptake of curcumin being developed

Scientists are reporting development of a nano-size capsule that boosts the body's uptake of curcumin, an ingredient in yellow curry now being evaluated in clinical trials for treatment of several diseases. Their study is in ACS' Journal of Agricultural and Food Chemistry, a bi-weekly publication.

5 Nov 2009

Study indicates possibility of a vaccine to prevent Group B Streptococcus infection

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible. GBS is the most common cause of sepsis and meningitis in newborns in the United States, according to the Centers for Disease Control and Prevention (CDC). It can also cause severe illness in pregnant women, the elderly and adults with chronic illnesses.

31 Oct 2009

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Alkermes, Inc. today announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled study will assess the safety, tolerability and pharmacokinetic effects of a single oral administration of five doses of ALKS 37 in approximately 40 healthy volunteers.

27 Oct 2009

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and nine months ended September 30, 2009.

27 Oct 2009

Phase 3 trial results of Horizon Therapeutics's HZT-501 presented at the ACG meeting

Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today presented an analysis from two pivotal Phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine.

27 Oct 2009

Analysis from Phase 3 trials of HZT-501 presented at 74th ACG meeting

26 Oct 2009

Eat healthy food to keep bacteria in the gut healthy

Healthy eating, not supplements, is the best way to keep the good bacteria in your gut healthy, says a dietitian and researcher.

22 Oct 2009

Logical Therapeutics to present its clinical study results on LT-NS001

Logical Therapeutics, Inc. (Logical), a biopharmaceutical company focused on developing products that treat medical conditions associated with inflammation, has been selected to present the results of its clinical study comparing the gastrointestinal (GI) safety of its lead product LT-NS001, vs. naproxen at the American College of Gastroenterology's (ACG) Annual Scientific Meeting on October 27, 2009.

21 Oct 2009

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Analysis of a small number of marker genes may determine in a matter of hours if a patient with gastrointestinal stromal tumors (GIST) would respond to a targeted molecular drug regimen. This analysis could allow clinicians to determine if they have chosen the best course of action or need to consider another alternative.

15 Oct 2009

New findings on genetic disorder may lead to better treatment of inflammatory bowel disease

New findings related to an uncommon genetic disorder may impact the diagnosis and treatment of inflammatory bowel disease (IBD), the most common chronic gastrointestinal illness in children and teens.

9 Oct 2009

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 1 study of PV-10 for liver cancer. The study will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company’s lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma.

1 Oct 2009

Results from COGENT clinical trial presented at TCT symposium

Results from a late breaking clinical trial called COGENT demonstrate that the combination of giving patients clopidogrel, a blood thinner commonly prescribed to patients with cardiovascular disease, and stomach medicines such as omeprazole, known as proton pump inhibitors (PPIs), did not lead to adverse events, as some prior studies had suggested.

25 Sep 2009

NIH awards Vaxart $2.8M grant to develop an orally-delivered H5N1 Avian influenza vaccine

Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has been awarded a $2.8 million phase II Small Business Innovation Research grant from the National Institute of Allergy and Infectious Disease (National Institutes of Health) to support development of its first product, an orally-delivered vaccine for H5N1 Avian influenza.

9 Sep 2009

Recruitment for the Phase IIa clinical trial to assess CNS 7056 sedative completed by PAION

The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces the successful completion of the Recruitment for the Phase IIa clinical trial assessing the new short-acting intravenous anesthetic/sedative CNS 7056 in patients undergoing endoscopy of the upper gastrointestinal tract.

8 Sep 2009

Natural food compounds may play a vital role in cancer treatment

Research in the Linus Pauling Institute at Oregon State University suggests that some natural food compounds, which previously have been studied for their ability to prevent cancer, may be able to play a more significant role in treating it - working side-by-side with the conventional drugs that are now used in chemotherapy.

1 Sep 2009

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease.

31 Aug 2009

New noninvasive technique to detect colorectal and gastric cancers found

A preliminary evaluation of methylation of two gene promoters in fecal DNA showed promise as a noninvasive method to detect colorectal and gastric cancers, according to a new study published online August 21 in the Journal of the National Cancer Institute.

24 Aug 2009

Depomed reports promising results in phase I trial for DM-1992 in Parkinson’s

Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson’s patients, DM-1992, Depomed’s investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa’s efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.

11 Aug 2009

Gastrointestinal Tract News and Research

World's smallest gastrointestinal videoscope with four-way angulation and NBI

ImmunoLin provides immediate benefit to the function of immune system and gut

Nano-size capsule that boosts the body's uptake of curcumin being developed

Study indicates possibility of a vaccine to prevent Group B Streptococcus infection

Alkermes commences ALKS 37 phase 1 clinical trial for the treatment of opioid-induced constipation

Lexicon Pharmaceuticals reports fiscal 2009 third-quarter results and updates of its clinical trials

Phase 3 trial results of Horizon Therapeutics's HZT-501 presented at the ACG meeting

Analysis from Phase 3 trials of HZT-501 presented at 74th ACG meeting

Eat healthy food to keep bacteria in the gut healthy

Logical Therapeutics to present its clinical study results on LT-NS001

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

New findings on genetic disorder may lead to better treatment of inflammatory bowel disease

Provectus Pharmaceuticals commences Phase 1 study of PV-10 for liver cancer

Results from COGENT clinical trial presented at TCT symposium

NIH awards Vaxart $2.8M grant to develop an orally-delivered H5N1 Avian influenza vaccine

Recruitment for the Phase IIa clinical trial to assess CNS 7056 sedative completed by PAION

Natural food compounds may play a vital role in cancer treatment

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

New noninvasive technique to detect colorectal and gastric cancers found

Depomed reports promising results in phase I trial for DM-1992 in Parkinson’s

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News